Vaxcyte

ISIN US92243G1085

 | 

WKN A2P6R6

Market cap (in EUR)
4,965 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.
Show more Show less
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals United States

Financials

Key metrics

Market capitalisation, EUR 4,965 m
EPS, EUR -4.46
P/B ratio 2.0
P/E ratio -
Dividend yield 0.00%

Income statement (2024)

Revenue, EUR -
Net income, EUR -429 m
Profit margin -

What ETF is Vaxcyte in?

There are 4 ETFs which contain Vaxcyte. All of these ETFs are listed in the table below. The ETF with the largest weighting of Vaxcyte is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
ETF Weight Investment focus Fund size (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.50%
Equity
United States
Health Care
Biotech
43
Vanguard ESG Global All Cap UCITS ETF (USD) Distributing 0.01%
Equity
World
Social/Environmental
488
Vanguard ESG North America All Cap UCITS ETF (USD) Distributing 0.01%
Equity
North America
Social/Environmental
27
JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist) 0.09%
Equity
United States
Small Cap
180
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.